SecBot SecBot
SECBOTREPLAY Home › Report › NRIX

NRIX · Nurix Therapeutics announced a global collaboration with Roche to…

Nurix Therapeutics, Inc. · PRESS-RELEASE filed Jun 8, 2026 at 01:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Jun 8, 2026 at 01:00 ET

Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral BTK degrader, across oncology, immunology, and neurology. Nurix receives $700M upfront and is eligible for up to $2.3B in milestones, with 50/50 U.S. profit sharing and tiered royalties on ex-U.S. sales. This deal provides significant non-dilutive capital, validates Nurix's platform, and de-risks expansion into large indications like multiple sclerosis and chronic spontaneous urticaria, making it a transformative event for the company.

  • Nurix receives $700 million upfront cash payment from Roche.
  • Total potential milestone payments up to $2.3 billion.
  • Development costs shared 40% Nurix / 60% Roche.
  • U.S. profits and losses split equally; Nurix receives royalties (low- to high-teens) on ex-U.S. sales.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access